SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff is driving attention, with traders pointing to leveraged long liquidations and broader risk-off pressure. The community is split between buying an oversold dip near technical support and expecting further declines if selling continues.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Phase 3 REGAL trial of GPS has reached the 80th event, and the company expects topline results this month, driving intense attention ahead of the AML data readout. Traders celebrated a sharp after-hours move and speculated about a data leak or short covering, while others cautioned that the trial remains blinded and its outcome is unknown.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs decision to remove Strategy from its indexes is fueling concerns about passive fund selling, while Bitcoins decline adds pressure to the stock. Traders debate whether the potential outflows are already priced in and whether the exclusion will materially weaken Strategys Bitcoin-linked financing model.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints from users whose work was interrupted. Traders debated whether the prolonged disruption should pressure the stock, which held near flat-to-positive, while some speculated about a cyberattack without confirmation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRP is sliding alongside a broader crypto selloff, with traders pointing to risk-off sentiment, inflation and rate-hike concerns, and leveraged liquidations. The steep decline has sparked debate over whether support will hold or losses will deepen, while some holders are buying the dip and others cite stalled regulatory progress and weak demand as reasons for caution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs resignation and Colette Kresss interim appointment have rattled NVDA shares, with traders also debating potential China chip-export scrutiny and the companys reliance on Huangs leadership. The community is split between buying the selloff on confidence in Nvidias AI business and avoiding the stock amid leadership and regulatory uncertainty.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,962,604.07029401. The last known price of Zcash is 956.58767703 USD and is down -2.92 over the last 24 hours. It is currently trading on 670 active market(s) with $828,877,374.43 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp pullback after a major rally is dominating discussion, with traders debating whether it is a broader crypto-market correction and liquidation flush or a deeper breakdown. Some call the selloff an oversold buying opportunity, while bears point to lost support and continued selling.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels planned prostate-cancer BLA filing has been pushed to mid-2027 amid FDA discussions and assay refinement, prompting a sharp selloff and criticism of managements communication and credibility. Some traders see the delay as a manufacturing and regulatory hurdle rather than a problem with the clinical data, while others remain concerned about execution and the longer wait.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is under pressure alongside Bitcoins slide and broader weakness in crypto-linked stocks, with traders highlighting fresh lows and arguing over whether the selloff has further to run or the shares are forming a base. Some also point to COINs underperformance versus Bitcoin and concerns about trading activity, while a smaller group sees an oversold bounce opportunity.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is drawing attention amid weakness in Ethereum and broader crypto-linked stocks, with traders focused on its ETH-treasury exposure and the shares decline. The community is split between dip-buyers expecting a recovery and critics questioning Tom Lees strategy, company spending, transparency and buybacks.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aarti Pharmalabs Gets 1 Observation in USFDA Inspection at Tarapur Unit

Mumbai: Aarti Pharmalabs Limited has successfully completed an inspection … any significant compliance issues. Aarti Pharmalabs further stated that it will … the stipulated timeline. Also Read: Aarti Drugs gets USFDA EIR for Tarapur …

Brief India: Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth and more

In this briefing: Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong JK Lakshmi Cement Limited - Lower Realisation Impacted Performance; Retain BUY Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 1. Signature Global Ltd - Q3FY26: Slow Quarter; Entering Phase of Steady Growth Maturing Gurugram Micro-Markets: Signature Global’s portfolio remains heavily concentrated in the micro-markets of Gurugram. Housing demand in Gurugram is transitioning from a fast, hype-driven phase to a more stable, end-user-led market. As a result, the company’s annual pre-sales are likely to normalise at around ~Rs 10,000 Cr, with price growth moderating to gradual high single digits. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong and more

In this briefing: Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong JK Lakshmi Cement Limited - Lower Realisation Impacted Performance; Retain BUY Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 India: Trade Agreements to Attract Foreign Investment 1. Westlife Foodworld Ltd - Demand Recovery Brewing; Margins Stay Strong Demand recovery combined with strong value strategy: The company is witnessing a clear improvement in guest counts from December onwards, with January trends continuing to remain positive. The Rs 99 value platform has now been rolled out across the West and select South markets without any adverse impact on gross margins, underscoring effective cost control. Management’s focus remains firmly on driving higher footfalls rather than only increasing ticket size, which is an appropriate strategy in a soft demand environment. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY and more

In this briefing: Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Aarti Drugs Ltd - Operational Headwinds Cloud Q3FY26 India: Trade Agreements to Attract Foreign Investment India: EU FTA, US Tariff Reductions Dovetail with Budget's Manufacturing Focus Aequitas: Turtlemint Fintech Solutions Limited Pre-IPO Tearsheet 1. Trent Ltd - Short-Term Noise, Long-Term Story Intact; Maintain BUY Revenue Performance: Trent posted a 16% YoY revenue growth in Q3FY26, with sales reaching Rs 5,259 Cr. However, the early festive season and the transition to the revised GST structure impacted QoQ comparability. In the near term, consumers showed a preference for higher-value purchases that benefited more from GST reductions, though demand for lower-ticket discretionary categories is expected to normalise over the medium term. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Healthcare: Primer: HeXun Biosciences (6986 TT) - Nov 2025 and more

In this briefing: Primer: HeXun Biosciences (6986 TT) - Nov 2025 Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. Primer: HeXun Biosciences (6986 TT) - Nov 2025 HeXun Biosciences operates a unique and synergistic dual-strategy business model, leveraging stable cash flow from its Contract Development and Manufacturing Organization (CDMO) services to fund its in-house development of high-potential stem cell-based new drugs. The company is strategically positioned in the high-growth regenerative medicine and biologics markets, with a focus on mesenchymal stem cells (MSCs) for cardiovascular diseases, a leading cause of death globally. Recent financial performance demonstrates exceptional growth, with revenue increasing by 119.36% and net income by 339.62% in the most recent fiscal year, transitioning the company from a loss-making entity to a profitable one with strong margin expansion.

Brief Healthcare: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook and more

In this briefing: Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 1. Classys (214150 KQ/Buy)Targeting Brazil with a Proven M&A Playbook For 3Q25, Classys reported in-line revenue of W83bn (+40% YoY) and below-consensus operating profit of W37.6bn (+30% YoY; OP margin of 45.3%). By category, aesthetic device revenue grew 30% YoY to W42.9bn, consumables revenue expanded 46% YoY to W37.3bn, and other revenue surged 310% YoY to W2.7bn. By region, domestic revenue climbed 57% YoY to W29.8bn, and overseas revenue increased 32% YoY to W53bn. Excluding Brazil, overseas revenue expanded 80% YoY. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Healthcare: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... and more

In this briefing: Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Primer: Classys (214150 KS) - Nov 2025 Canbas Co Ltd (4575 JP): Q1 FY 06/26 flash update 1. Krishna Institute of Medical Sciences Ltd - Expansion-Led Growth Continues... Revenue In Line; Profitability Impacted by New Units: KIMS reported revenue broadly in line with our estimates, while EBITDA and PAT came in below expectations due to the initial ramp-up of new hospitals and the resultant operating deleverage. Profitability was impacted by higher depreciation and interest costs associated with the new facilities introduced. Reported revenue stood at 961 Cr, with margins at 21.2%, impacted by the addition of new units. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Growth Ideas: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

In this briefing: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch 1. VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY Robust Execution and Order Pipeline to Fuel H2FY26 Growth: Wabag delivered a 19% YoY growth in revenue for Q2FY26, broadly meeting our estimates. Revenue recognition is typically skewed towards the second half of the year, indicating strong H2. The management mentioned that margins may vary on a quarterly basis, while the medium-term margin outlook remains intact. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief Equities Bottom-Up: VA Tech Wabag Ltd - Robust Orderbook Reassures Long-Term Growth; Maintain BUY and more

Brief Equities Bottom-Up: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 and more

In this briefing: KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Embassy Office Parks REIT Ltd - Q2FY26: Expansion on Track; Healthy NOI Aarti Drugs Ltd - Capacity Ramp-Up and Margin Gains Fuel Performance Global Health Ltd - Strengthening Network with Noida Launch Calix’s Next Frontier: Can MDUs & International Push Boost Its Market Performance? 1. KPIT Technologies Ltd - Impact of Acquisition Spends; Significant Recovery from FY27 Macro Environment Outlook: The overall macro environment has shown a marked improvement, with uncertainty levels reducing by over 50% compared to Q4FY25. Europe displayed strong traction during the quarter as clients began transitioning their supply chains from local to more globally integrated ecosystems. Deal Wins/Pipeline: The company announced a major multi-year, multi-domain deal from a leading European OEM. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Aarti Drugs Ltd. engages in the development, manufacture and market of pharmaceutical products. The firm operates through the Out of India, and India geographical segments. Its products include active pharmaceutical ingredient, specialty chemicals, pharma intermediate, products under development, and product under pipeline. The company was founded on September 28, 1984 and is headquartered in Mumbai, India.

Current Price	516.80
Prev Close	510.60
Open	509.20
Dividend Yield	N/A
50-Day Moving Average	428.17
Beta	N/A
Avg. Volume	687,503.91
PE Ratio	20.29

52-Week High	514.10
52-Week Low	318.95
Market Capitalization	44.9B
EPS (Annual)	21.36
Price to Book	2.76
Revenue Per Employee	9.03M

Feed

News

Sentiment

Fundamentals

Info

AARTIDRUGS.NSE Fundamentals